NASDAQ: EXAS 47.54
Change: -5.42 -10.23% Minimum 20 min delay
3:08 PM ET on Jan 17, 2018
Volume: 12,523,609

Exact Sciences to host second-quarter 2016 results, annual meeting webcasts and calls

06/29/2016

MADISON, Wis., June 29, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls to discuss its second-quarter 2016 financial results and for its annual stockholders meeting.

Exact Sciences Corporation Logo (PRNewsFoto/EXACT SCIENCES CORPORATION)

Second-Quarter 2016 Webcast & Conference Call Details

    Date:          

Tuesday, July 26, 2016

    Time:        

10 a.m. ET, 9 a.m. CT

    Webcast:        

The live webcast can be accessed at www.exactsciences.com

    Telephone:          

Domestic callers, dial 877-212-6082             


International callers, dial 707-287-9332


Access code for both domestic and international callers: 42743449

Annual Meeting of Stockholders Webcast & Conference Call Details

    Date:             

Thursday, July 28, 2016

    Time:            

11 a.m. ET, 10 a.m. CT

    Webcast:       

The live webcast can be accessed at www.exactsciences.com

    Telephone:       

Domestic callers, dial 877-212-6082             


International callers, dial 707-287-9332


Access code for both domestic and international callers: 42968129

An archive of each webcast will be available at www.exactsciences.com. A replay of both the second-quarter and annual meeting conference calls will be available by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the replay of the second-quarter call is 42743449.  The annual meeting replay can be accessed with the code 42968129.  The webcasts, conference calls and replays are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard, the company's FDA-approved, multi-target stool-DNA based colorectal cancer screening test, is included in the colorectal cancer screening recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society (2014), and stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008) and American College of Gastroenterology (2009). For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and health care providers; the willingness of health insurance companies and other payors to reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of any healthcare reforms, including without limitation the Affordable Care Act, or changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and/or quality-of-care metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative and licensing arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; the impact of our nationwide television advertising campaign; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
J.P. Fielder
Senior Director, Corporate Communications, Exact Sciences Corp.
608-210-5220
jpfielder@exactsciences.com

Logo - http://photos.prnewswire.com/prnh/20160108/320353

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exact-sciences-to-host-second-quarter-2016-results-annual-meeting-webcasts-and-calls-300291791.html

SOURCE EXACT SCIENCES CORP